NASDAQ:KURA - Kura Oncology Stock Price, Forecast & News

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Kura Oncology Inc (NASDAQ:KURA) released its earnings results on Tuesday, November, 5th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.03. View Kura Oncology's Earnings History.

Kura Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Kura Oncology.

Kura Oncology will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 equities research analysts have issued 12-month price targets for Kura Oncology's stock. Their forecasts range from $22.00 to $30.00. On average, they anticipate Kura Oncology's stock price to reach $26.83 in the next year. This suggests a possible upside of 120.5% from the stock's current price. View Analyst Price Targets for Kura Oncology.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.

News articles about KURA stock have been trending extremely negative on Thursday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kura Oncology earned a media sentiment score of -4.6 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Kura Oncology.

Kura Oncology saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,530,000 shares, an increase of 26.5% from the January 15th total of 2,000,000 shares. Based on an average daily volume of 293,700 shares, the short-interest ratio is currently 8.6 days. Approximately 6.2% of the shares of the stock are sold short. View Kura Oncology's Current Options Chain.

Some companies that are related to Kura Oncology include Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), Pacira Biosciences (PCRX), Xencor (XNCR), Cambrex (CBM), Esperion Therapeutics (ESPR), Eidos Therapeutics (EIDX), Ironwood Pharmaceuticals (IRWD), Forty Seven (FTSV), Heron Therapeutics (HRTX), Zymeworks (ZYME), Tricida (TCDA), Aimmune Therapeutics (AIMT), Ligand Pharmaceuticals (LGND) and Arvinas (ARVN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Inovio Pharmaceuticals (INO), Amarin (AMRN), Exelixis (EXEL), Agile Therapeutics (AGRX), Aduro BioTech (ADRO), Advanced Micro Devices (AMD), Corbus Pharmaceuticals (CRBP), Fate Therapeutics (FATE), Viking Therapeutics (VKTX) and vTv Therapeutics (VTVT).

Kura Oncology's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), EcoR1 Capital LLC (9.36%), Victory Capital Management Inc. (5.26%), Victory Capital Management Inc. (5.24%), Eagle Asset Management Inc. (4.55%) and State Street Corp (2.34%). Company insiders that own Kura Oncology stock include Antonio Gualberto and Ecor1 Capital Fund Qualified,. View Institutional Ownership Trends for Kura Oncology.

KURA stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Driehaus Capital Management LLC, State Street Corp, Man Group plc, SG Americas Securities LLC, Oak Ridge Investments LLC, UBS Group AG and Rafferty Asset Management LLC. View Insider Buying and Selling for Kura Oncology.

KURA stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., EcoR1 Capital LLC, Point72 Asset Management L.P., WCM Investment Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., FMR LLC and Pathway Capital Management LP. View Insider Buying and Selling for Kura Oncology.

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KURA stock can currently be purchased for approximately $12.17.

Kura Oncology has a market capitalization of $551.48 million. The company earns $-60,450,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.View Additional Information About Kura Oncology.

The official website for Kura Oncology is http://www.kuraoncology.com/.

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]